#USA #Waltham #Q32 Bio #Bempikibart #Alopecia Areata

Q32 Bio Announces Key Findings at EADV Congress 2026

Q32 Bio Inc., a clinical-stage biotechnology firm, has confirmed its participation in the European Academy of Dermatology and Venereology (EADV) Congress scheduled from September 30 to October 3, 2026. At this prominent event, the company will feature late-breaking presentations regarding interim results from Part B of the SIGNAL-AA clinical trial, focusing on their innovative treatment, Bempikibart, for alopecia areata (AA).

Understanding Alopecia Areata and the Role of Bempikibart

Alopecia areata is an autoimmune disorder that leads to hair loss and has a significant emotional and psychological impact on individuals affected. It is estimated that around 700,000 people in the U.S. suffer from this condition, with limited effective treatment options currently available. Bempikibart, a fully human anti-IL-7Rα antibody, aims to address this issue by re-regulating immune function and potentially restoring hair growth.

Presentation Highlights

The oral and poster presentations will unveil critical findings, including:

• - Additional 36-week Results: These findings give more insight into the efficacy of Bempikibart in treating AA.
• - Initial Off-Drug Data: This encompasses a 16-week period where participants were off treatment, providing valuable information on the persistence of treatment effects and safety.

Oral Presentation Details

• - Title: Bempikibart, a novel IL-7Rα antibody, demonstrates hair regrowth that extends beyond treatment duration in severe AA cases.
• - Presenter: Arash Mostaghimi, M.D., Associate Professor of Dermatology at Brigham and Women’s Hospital, and Vice Chair of Clinical Trials and Innovation at Harvard Medical School.
• - Session Timing: September 30, 2026, at 3:15 PM CEST.
• - Location: Hall A of the EADV venue in Vienna.

Poster Presentation Details

• - Title: Preliminary findings from the Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart in patients with severe AA.
• - Presenter: Arash Mostaghimi, M.D.
• - Session Timing: September 30, 2026, at 7:00 AM CEST.
• - Location: Poster Area of the conference.

A Commitment to Innovation

Jodie Morrison, CEO of Q32 Bio, emphasized the significance of these presentations by stating, "Our commitment to providing a targeted therapy for those affected by alopecia areata is evident in these late-breaking results. The unique mechanism of Bempikibart is set to potentially redefine treatment standards in this field."

The presentations will be accessible on the Q32 Bio website post the EADV Congress, allowing the global scientific community to review the findings in detail.

Future Prospects and Initiatives

As Q32 Bio continues to advance its clinical development, insights gained from the SIGNAL-AA trial could also have implications for other autoimmune diseases, further extending the benefits of Bempikibart beyond alopecia areata. This is crucial as the company aspires to broaden its impact on patients dealing with autoimmune and inflammatory disorders.

Conclusion
The upcoming EADV Congress holds great promise for Q32 Bio, not only as a platform for showcasing pivotal research but also as an opportunity to engage with healthcare professionals and stakeholders in the dermatology space. The results from the SIGNAL-AA clinical trial are a step forward in providing better treatment options for millions affected by alopecia areata, emphasizing the importance of innovation in biopharmaceutical development.